Frank Rimerman Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Frank Rimerman Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Buy	3,317 +35	+1%	+$16.3K	0.1%	167
2025 Q4	$1.49M	Buy	3,282 +162	+5%	+$69.8K	0.09%	169
2025 Q3	$1.22M	Sell	3,120 -126	-4%	-$52.7K	0.08%	200
2025 Q2	$1.45M	Sell	3,246 -304	-9%	-$140K	0.1%	155
2025 Q1	$1.72M	Buy	3,550 +278	+8%	+$130K	0.14%	119
2024 Q4	$1.32M	Sell	3,272 -2,036	-38%	-$944K	0.1%	151
2024 Q3	$2.47M	Sell	5,308 -1	-0%	-$480	0.18%	101
2024 Q2	$2.49M	Buy	5,309 +5,297	+44,142%	+$2.3M	0.18%	96
2024 Q1	$5.02K	Hold	12	–	–	﹤0.01%	208
2023 Q4	$4.88K	Buy	+12	New	+$4.43K	﹤0.01%	201

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Frank Rimerman Advisors's VRTX Position: Q1 2026 in Review

Frank Rimerman Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, buying an estimated $16.3K and bringing the position to 3,317 shares worth $1.48M. The position accounts for 0.1% of the portfolio, ranked #167.

Frank Rimerman Advisors first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.49M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Frank Rimerman Advisors held 3,317 shares of Vertex Pharmaceuticals worth $1.48M as of Q1 2026.
Frank Rimerman Advisors bought 35 Vertex Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
Vertex Pharmaceuticals made up 0.1% of Frank Rimerman Advisors's portfolio in Q1 2026, its #167 holding.
Frank Rimerman Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Frank Rimerman Advisors's Vertex Pharmaceuticals position peaked at $2.49M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.